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Abstract
Background: Combination of platinum derivatives with paclitaxel is currently the standard front line
regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients
with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability
represents one of the potential methods of noninvasive laboratory assessment of gastrointestinal
mucositis induced by chemotherapy, but little is known about intestinal permeability in patients treated
with paclitaxel or platinum.
Methods: Intestinal permeability was assessed in 36 breast and ovarian cancer patients treated with
paclitaxel/platinum combination by measuring, using capillary gas chromatography, urinary sucrose,
lactulose, xylose and mannitol after oral challenge. The significance of differences during the therapy
compared to pre-treatment values was studied by Wilcoxon paired test. The differences between groups
of patient were studied by Mann-Whitney U test. Fisher exact test was used to compare the frequency in
different subgroups.
Results: After administration of the first dose, a significant (p < 0.05) decrease in xylose absorption and
increased lactulose/mannitol, sucrose/mannitol, lactulose/xylose and sucrose/xylose ratios were observed,
but these parameters returned subsequently to pre-treatment levels. Patients who experienced serious
(grade 3 or 4) toxicity had at baseline significantly lower percentages of xylose, mannitol and sucrose, and
higher lactulose/mannitol ratio. Nine of 13 (69%) patients with baseline lactulose/mannitol ratio 0.070 or
above experienced serious toxicity compared to 4 out of 23 patients (17%) with the ratio below 0.070 (p
= 0.002). Post-treatment lactulose, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were
significantly increased in patients with serious toxicity.
Conclusion: A transient significant increase in lactulose/monosaccharide and sucrose/monosaccharide
ratios was observed in ovarian and breast cancer patients treated with paclitaxel and platinum. Increased
lactulose absorption, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were evident in
patients with grade 3 or 4 toxicity, and increased baseline lactulose/mannitol ratio predicted serious
toxicity.
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Background
Combination of platinum derivatives (cisplatin or carbo-
platin) with paclitaxel is currently the standard front line
regimen for patients with advanced epithelial ovarian car-
cinoma (EOC) after demonstration of superior survival in
randomized clinical trials [1,2]. This combination is also
highly active in patients with metastatic breast carcinoma
[3], or in patients with unknown primary carcinoma [4].
Hematologic toxicity (neutropenia, thrombocytopenia
and anemia) is the most important side effect of paclit-
axel/platinum combination, but, similarly to many other
regimens of cytotoxic chemotherapy, gastrointestinal
mucositis is common in patients treated with paclitaxel/
platinum. The term gastrointestinal mucositis is used to
describe the damage of mucosa distal to oral cavity
induced by cytotoxic drugs or radiation [5,6]. Any part of
the gastrointestinal tract from the oral cavity to the anus
may be affected. Depending on the region of gastrointes-
tinal tract affected, gastrointestinal mucositis may mani-
fest as dysphagia, dyspepsia, diarrhea, abdominal
cramping, or rectal bleeding. The incidence of severe gas-
trointestinal mucositis in patients treated with taxane/
platinum combination is around 15% [1,7], but clinical
manifestations of gastrointestinal mucositis of milder
degree are found in most patients treated with paclitaxel/
platinum. In addition, management of gastrointestinal
mucositis may be a problem in EOC patients with gas-
trointestinal function compromised as a consequence of
involvement of peritoneal cavity by the tumor, or ablative
surgery.
While mucosal damage in the oral cavity can be easily
assessed by direct inspection, involvement of other
regions of the gastrointestinal tract may be evaluated
solely by endoscopy, which is less easily performed in a
patient coping with the side effects of anti-cancer therapy.
The diagnosis and the assessment of severity of gastroin-
testinal mucositis therefore still rely on anamnestic data.
Intestinal permeability is used to study the disorders of
gut mucosa in benign disorders, such as inflammatory
bowel disease and gluten enteropathy [8,9]. The measure-
ment of absorption of biologically inert sugars has been
used for the estimation of intestinal permeability in most
studies, usually combining a disaccharide and a monosac-
charide with the results of differential excretion expressed
as a ratio. Under physiological conditions, monosaccha-
rides are readily absorbed by the intestinal villi, while dis-
accharides that are absorbed in the crypt epithelium are
excluded. Atrophy of the villi may result in the decrease in
monosaccharide absorption and increased exposure of
the crypts to luminal contents. The dysfunction of small
bowel mucosa is therefore characterized by an increase in
disaccharide/monosaccharide (e.g. lactulose/mannitol)
ratio. In addition to the assessment of the function of
small intestine, dysfunction of gastroduodenal mucosa
may be assessed using sucrose, a disaccharide normally
digested in the small intestine [10]. Intestinal permeabil-
ity has also been investigated in patients treated with cyto-
toxic drugs. Alterations of intestinal permeability similar
to those found in patients with benign intestinal disorders
were found after administration of different cytotoxic
agents, including fluoropyrimidines, alkylating com-
pounds and anthracyclines [11], but there is virtually no
information on intestinal permeability in patients treated
with a taxane/platinum combination.
In the present study, we investigated intestinal permeabil-
ity in ovarian and breast cancer patients treated with pacl-
itaxel and platinum chemotherapy.
Methods
Patients
A total of 36 women, mean (± standard deviation) age 57
± 11 (range 34 – 79) years, treated with paclitaxel and
platinum derivatives were included in the present study.
Fifteen patients had ovarian cancer (primary EOC 13
patients and Krukenberg tumors 2 patients), 19 patients
had breast carcinoma and 2 patients had adenocarcinoma
of unknown primary (Table 1). Five patients with primary
EOC also had a history of breast cancer. Ten patients were
chemotherapy-naïve and 26 patients had a history of pre-
vious chemotherapy. Twenty-one patients were treated
with the combination of paclitaxel (175 mg/m2 for 1 to 3
hours) and carboplatin (area under the curve 6) adminis-
tered every 3 weeks. One patient with carboplatin allergy
received the combination of paclitaxel (175 mg/m2) and
cisplatin (75 mg/m2). Thirteen patients were treated with
a weekly regimen of paclitaxel (90 mg/m2) with carbopl-
atin (area under the curve 2) with (9 patients) or without
trastuzumab (4 mg/kg loading dose, then 2 mg/kg weekly;
4 patients), and one patient, who was originally consid-
ered for the combination chemotherapy with carboplatin,
was subsequently treated with the weekly regimen of pacl-
itaxel and trastuzumab. The toxicity was assessed using
Common Terminology Criteria for Adverse Events version
3.0 [12]. Serious toxicity was defined as of grade 3 or
higher. The protocol was approved by the University Hos-
pital Hradec Králové Ethics Committee, and the patients
signed informed consent.
Measurement of intestinal permeability
Intestinal permeability was studied by measuring urinary
sucrose, lactulose, xylose and mannitol after oral chal-
lenge [13]. After an overnight fast, a pre-test urine sample
was collected to detect any endogenous mannitol and the
patients ingested 100 ml of the test solution containing 2
g of mannitol, 2 g of xylose, 10 g of lactulose, and 25 g of
sucrose in water. The patients then continued fasting for 2BMC Cancer 2007, 7:155 http://www.biomedcentral.com/1471-2407/7/155
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hours, and urine was collected for 5 hours. Urine samples
were stored at -24°C until analysis.
Lactulose, xylose, sucrose and mannitol were determined
by capillary gas chromatography as described [13], and
urinary excretion was expressed as percentage of the
ingested dose as well as the ratio of lactulose/mannitol,
sucrose/mannitol, lactulose/xylose and sucrose/xylose.
All chemicals were obtained from Sigma (St. Louis, MO,
USA). Briefly, samples were thawed, spiked with internal
standard (phenyl-β-D-glucoside) and evaporated under
vacuum to dryness (Eppendorf Concentrator 5301,
Eppendorf, Hamburg, Germany). The dried residues were
derivatized by hydroxylamine in pyridine (75°C for 30
minutes) and bis(trimethylsillyl)trifluoracetamide (75°C
for 15 minutes). The aliquot of the sample was injected
into gas chromatograph equipped with a non-polar col-
umn and flame ionization detector (GC 8000, Fisons
Instruments, Milano, Italy). Chromatographic data were
collected using Clarity software (DataApex, Prague, Czech
Republic). The method is specific as no interfering peaks
were found, and other mono- and disaccharides did not
interfere with the sugars used for gastroduodenal and
intestinal permeability testing. The detection limit (10
mg/l) and quantitation limit (50 mg/l) were identical for
mannitol, xylose, sucrose and lactulose, and reproducibil-
ity calculated as coefficient of variation was consistently
below 7%. The quality control was performed by the
measurement of customized stored quality control sam-
ples along with each set of specimens.
The test was performed before the start of therapy (base-
line), during the first cycle of chemotherapy (one week
after the start of treatment), at the end of the first or sec-
ond cycle of chemotherapy, and before subsequent chem-
otherapy cycles.
Table 1: Characteristics of patients
patient age (years) diagnosis previous 
chemotherapy
regimen timing of 
measurement 
after the first 
dose (days 
from start)
toxicity during first 6 
weeks of therapy 
(grade)
baseline 
lactulose/
mannitol ratio
lactulose/
mannitol ratio 
after the first 
dose
1 52 EOC (history of BC) yes q3w (cisplatin) 6 diarrhea (2) 0.069 0.033
2 66 EOC none q3w 7 diarrhea (1) 0.030 0.011
3 67 EOC (history of BC) none q3w 7 none 0.096 0.047
44 6 E O C y e s q 3 w 7 neutropenia (3) 0.027 0.079
5 52 EOC none q3w 7 none 0.017 0.017
6 39 unknown primary none q3w 6 none 0.044 0.021
7 39 Krukenberg yes q3w 7 diarrhea (3) 0.111 0.132
8 62 EOC (history of BC) yes q3w 4 none 0.090 0.018
97 1 E O C y e s q 3 w 7 neutropenia (4) 0.108 0.770
10 67 EOC none q3w 7 leukopenia (2) 0.061 0.129
11 64 BC yes q3w 7 leukopenia (2) 0.041 0.144
12 56 EOC yes q3w 7 none 0.031 0.027
13 64 BC yes q3w 7 none 0.041 0.032
14 58 BC yes q3w 7 diarrhea (1) 0.026 0.132
15 60 BC yes q3w 7 none 0.033 0.054
16 45 BC yes q3w 7 none 0.033 0.110
17 54 BC yes q3w 7 nausea (3) 0.184 0.438
18 58 BC yes q3w 7 neutropenia (3) 0.038 0.057
19 61 unknown primary none q3w 6 diarrhea (2) 0.055 0.063
20 66 BC yes q3w 2 leukopenia (2) 0.031 0.040
21 46 EOC (history of BC) none q3w 7 none 0.047 0.029
22 52 EOC (history of BC) yes q3w 7 leukopenia (2) 0.063 0.119
23 59 BC yes weekly P+C+T 7 anemia (3) 0.072 0.094
24 78 BC yes weekly P+ T 7 diarrhea (3) 0.094 0.133
25 45 BC yes weekly P+C+T 7 none 0.069 0.128
26 63 BC none weekly P+C 7 none 0.075 0.060
27 36 Krukenberg yes weekly P+C 7 leukopenia (3) 0.072 0.106
28 57 BC yes weekly P+C+T 7 none 0.038 0.041
29 74 EOC none weekly P+C 2 nausea (3) 0.090 0.130
30 41 BC yes weekly P+C+T 22 neutropenia (4); 
stomatitis (3)
0.038 0.030
31 79 EOC none weekly P+C 3 nausea (3) 0.120 0.118
32 34 BC yes weekly P+C+T 7 none 0.025 0.010
33 63 BC yes weekly P+C+T 8 diarrhea (3) 0.075 0.070
34 55 BC yes weekly P+C+T 7 neutropenia (3) 0.043 0.069
35 62 BC yes weekly P+C+T 7 none 0.082 0.099
36 54 BC yes weekly P+C+T 7 none 0.030 0.044
Grade 3 or 4 toxicity is highlighted by bold type. BC breast carcinoma; C carboplatin; EOC epithelial ovarian carcinoma; q3w paclitaxel/carboplatin every 3 weeks (cisplatin in 
patient 1); P paclitaxel; T trastuzumabBMC Cancer 2007, 7:155 http://www.biomedcentral.com/1471-2407/7/155
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Statistical analysis
The significance of differences during the therapy com-
pared to pre-treatment values was studied by Wilcoxon
paired test. The differences between groups of patients
were studied by Mann-Whitney U test. Serial measure-
ments were evaluated using the means of subsequent
measurements as described [14], and these means of
measurements were compared with baseline values by
Wilcoxon paired test. Fisher exact test was used to com-
pare the frequency in different subgroups. The analyses
were performed using NCSS 2001 software (Number
Cruncher Statistical Systems, Kaysville, Utah, USA). The
decision on statistical significance was based on p = 0.05
level.
Results
Intestinal permeability during the therapy with paclitaxel/
platinum
No significant differences were observed at baseline in the
parameters of intestinal permeability between patients
with ovarian cancer, and breast or unknown primary car-
cinomas, with the exception of lower percentage of man-
nitol absorption in ovarian cancer patients (mean ±
standard error of the mean 8.7 ± 1.9% vs. 13.3 ± 1.6%, p
= 0.01). Similarly, no significant differences were
observed between chemotherapy-naïve patients and
patients who had previous chemotherapy.
In all patients, intestinal permeability was assessed during
the first cycle, 7 ± 3 days after the first dose of chemother-
apy. At this time point, a decrease in xylose absorption, an
increase in sucrose absorption of borderline significance
and significantly increased lactulose/mannitol, sucrose/
mannitol, lactulose/xylose (Figure 1), and sucrose/xylose
ratios were observed. Subsequently, at least one addi-
tional measurement was obtained in 32 patients. The rea-
son for no subsequent measurements in the remaining 4
patients was interruption of chemotherapy in 3 cases and
technical problems with sample collection in one case.
The median number of these additional measurements
was 3 (range 1 – 7). The earliest next measurement was
obtained 24 ± 9 days after the start of therapy (at the end
of the first or second chemotherapy cycle). At this time, all
parameters of intestinal permeability were not signifi-
cantly different from baseline (Table 2). Similarly, the
means of all measurements subsequent to the measure-
ment in the first cycle were not significantly different from
the baseline. The changes in intestinal permeability were
similar in patients treated with weekly or 3-week regimen
with the exception of percentage of xylose absorption that
remained unchanged in patients treated with weekly regi-
men.
Intestinal permeability and toxicity
A total of 13 patients experienced a serious toxicity (grade
3 or 4 adverse events) during the first 6 weeks of therapy
(grade 3 or 4 leukopenia or neutropenia 6 patients, grade
3 diarrhea 3 patients, grade 3 nausea 3 patients, and grade
3 anemia 1 patient). Compared to other patients, patients
who experienced serious toxicity had significantly lower
Table 2: Intestinal permeability before and during the therapy
parameter baseline (before 
therapy)
(mean ± SEM)
(95% CI)
(range)
after the first 
dose
(mean ± SEM)
(95% CI)
(range)
p (compared to 
baseline)
mean of 
subsequent 
measurements
(mean ± SEM)
(95% CI)
(range)
p (compared to 
baseline)
at the end of 
first or second 
cycle
(mean ± SEM)
(95% CI)
(range)
p (compared to 
baseline)
xylose (%) 17.1 ± 1.6
(13.9 – 20.2)
(0.8 – 45.3)
13.5 ± 1.5
(10.5 – 16.4)
(2.2 – 40.7)
0.03 16.2 ± 1.1
(14.0 – 18.5)
(4.2 – 35.5)
0.40 17.1 ± 1.6
(13.8 – 20.3)
(2.4 – 53.2)
0.41
mannitol (%) 11.4 ± 1.3
(8.8 – 14.0)
(0.5 – 34.2)
9.6 ± 0.9
(7.7 – 11.4)
(1.4 – 24.6)
0.21 13.1 ± 1.3
(10.4 – 15.9)
(2.0 – 36.2)
0.58 10.5 ± 1.0
(8.4 – 12.6)
(1.1 – 23.9)
0.16
sucrose (%) 0.41 ± 0.06
(0.30 – 0.52)
(0.05 – 1.40)
0.54 ± 0.07
(0.39 – 0.70)
(0.06 – 1.71)
0.06 0.47 ± 0.08
(0.30 – 0.64)
(0.08 – 2.51)
0.73 0.47 ± 0.09
(0.28 – 0.65)
(0.07 – 2.51)
0.43
lactulose (%) 0.57 ± 0.07
(0.42 – 0.73)
(0.06 – 2.40)
0.64 ± 0.07
(0.49 – 0.78)
(0.05 – 2.08)
0.46 0.56 ± 0.08
(0.41 – 0.72)
(0.12 – 2.19)
0.49 0.59 ± 0.10
(0.39 – 0.78)
(0.07 – 2.19)
0.30
lactulose/mannitol 
ratio
0.061 ± 0.006
(0.049 – 0.073)
(0.017 – 0.184)
0.101 ± 0.023
(0.055 – 0.147)
(0.010 – 0.770)
0.02 0.059 ± 0.006
(0.047 – 0.070)
(0.017 – 0.143)
0.54 0.058 ± 0.006
(0.045 – 0.071)
(0.009 – 0.136)
0.77
sucrose/mannitol 
ratio
0.038 ± 0.004
(0.030 – 0.046)
(0.008 – 0.098)
0.077 ± 0.017
(0.043 – 0.111)
(0.012 – 0.585)
0.004 0.048 ± 0.006
(0.035 – 0.061)
(0.008 – 0.154)
0.16 0.044 ± 0.006
(0.031 – 0.056)
(0.009 – 0.152)
0.37
lactulose/xylose 
ratio
0.039 ± 0.004
(0.030 – 0.047)
(0.014 – 0.139)
0.074 ± 0.016
(0.042 – 0.107)
(0.007 – 0.443)
0.004 0.041 ± 0.006
(0.027 – 0.054)
(0.008 – 0.166)
0.69 0.037 ± 0.006
(0.025 – 0.049)
(0.004 – 0.162)
0.90
sucrose/xylose 
ratio
0.024 ± 0.002
(0.019 – 0.029)
(0.004 – 0.061)
0.057 ± 0.011
(0.035 – 0.080)
(0.009 – 0.336)
0.001 0.034 ± 0.007
(0.020 – 0.048)
(0.004 – 0.186)
0.31 0.029 ± 0.006
(0.017 – 0.041)
(0.003 – 0.186)
0.74
Shown is the mean ± standard error of the mean (SEM) of respective parameters. 95% confidence intervals (CI) of the mean are highlighted by the bold type, and range is 
indicated in the parenthesis below.BMC Cancer 2007, 7:155 http://www.biomedcentral.com/1471-2407/7/155
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percentages of xylose, mannitol and sucrose, and higher
lactulose/mannitol ratio at baseline (Table 3). In addi-
tion, post-treatment lactulose, lactulose/mannitol,
sucrose/mannitol and lactulose/xylose ratios were signifi-
cantly increased in patients with serious toxicity. Thirteen
patients had baseline lactulose/mannitol ratio 0.070
(95% upper confidence limit of the mean of all patients)
or above. Nine of these patients (69%) experienced seri-
ous toxicity compared to 4 out of 23 patients (17%) with
lactulose/mannitol ratio below 0.070 (p = 0.003).
Discussion
Intestinal permeability had been previously studied in
cancer patients treated with different chemotherapy regi-
mens [15-19], and the present study extends the observa-
tions of alterations of intestinal permeability in patients
treated with anthracyclines, fluoropyrimidines and
alkylating agents to paclitaxel and platinum chemother-
apy. The present study included patients with ovarian can-
cer, breast cancer and unknown primary carcinoma
treated with different regimens of paclitaxel/platinum
chemotherapy, but no significant differences in gastroin-
testinal permeability were observed based on primary or
regimen of chemotherapy, and statistical analyses were
performed for the group as a whole. The rate of severe gas-
trointestinal mucositis induced by paclitaxel/platinum
combination chemotherapy is relatively low compared to
the incidence of myelosuppression in this patient popula-
tion. Grade 3 or 4 gastrointestinal mucositis has been
reported in 15% of patients treated with 3-week regimen
of paclitaxel with cisplatin [1], and similar incidence of
severe gastrointestinal mucositis has been reported for
paclitaxel/carboplatin combination [7,20]. Serious gas-
trointestinal mucositis is less frequent in patients treated
with weekly regimens [21]. However, some gastrointesti-
nal symptoms are observed in most patients treated with
paclitaxel/platinum combination [1,22], and manifesta-
tions of gastrointestinal mucositis have a major impact on
the quality of life. In the present study, we have observed
a transient increase in lactulose/monosaccharide (manni-
tol or xylose) ratios that returned later to pre-therapeutic
levels. Similarly, sucrose/monosaccharide ratios increased
during the first cycle indicating gastroduodenal mucositis.
While all patients had assessment of gastroduodenal and
intestinal permeability during the first chemotherapy
cycle, the number of subsequent measurements was dif-
ferent because of the differences in the duration of therapy
in individual patients. Because the numbers of measure-
ments in each patient were different, an additional analy-
sis was performed of the means of sequential
measurements as described by Matthews et al. [14].
Parameters of intestinal permeability assessed at the end
of the first or second cycle as well as the means of sequen-
tial measurement showed similar results.
Lactulose absorption, lactulose/mannitol, sucrose/man-
nitol and lactulose/xylose ratios during the first cycle of
chemotherapy were markedly increased in patients who
experienced toxicity, similarly to previous reports with
other regimens [18,19,23]. Moreover, patients who expe-
rienced grade 3 or 4 toxicity during the first 6 weeks of
treatment had significantly higher baseline lactulose/
mannitol ratio, and serious toxicity was four times more
common in patients with baseline lactulose/mannitol
ratio 0.070 or above. Because of limited number of
patients, no distinction was made with respect of the
nature of the toxic events, and patients with both gastroin-
testinal and hematological toxicity were included in the
analysis. Although an association between intestinal per-
meability and hematological toxicity could at first glance
seem surprising, similar observations indicating that the
dysfunction of small bowel mucosa could predispose a
subject also for hematological toxicity have been reported
previously [24]. An association between gastrointestinal
mucositis and increased disaccharide/monosaccharide
ratio has been so far reported in few studies [18,23,25],
but the present study may be the first report indicating
that increased lactulose/mannitol ratio could be a predic-
tor of toxicity. However, the potential use of intestinal
permeability measurements in the prediction of the toxic-
ity of chemotherapy should be assessed in a larger pro-
spective study.
The term intestinal permeability reflects the barrier func-
tion of bowel mucosa in separating the internal milieu
Lactulose/xylose ratio before and during therapy Figure 1
Lactulose/xylose ratio before and during therapy. Uri-
nary lactulose and xylose were determined after oral chal-
lenge before the treatment, during the first cycle and at the 
end of first or second cycle. Shown are results of measure-
ments obtained in individual patients.
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Table 3: Comparison between intestinal permeability before therapy and after the first cycle in patients with or without serious 
toxicity
parameter no serious toxicity
(n = 23)
(mean ± SEM)
(95% CI)
(range)
serious toxicity
(n = 13)
(mean ± SEM)
(95% CI)
(range)
p
baseline xylose (%) 19.2 ± 2.0
(15.2 – 23.3)
(2.6 – 45.3)
13.2 ± 2.4
(8.0 – 18.3)
(0.8 – 30.4)
0.05
baseline mannitol (%) 13.5 ± 1.7
(10.0 – 17.0)
(1.8 – 34.2)
7.6 ± 1.4
(4.6 – 10.7)
(0.5 – 18.1)
0.02
baseline sucrose (%) 0.47 ± 0.07
(0.33 – 0.62)
(0.05 – 1.40)
0.30 ± 0.09
(0.11 – 0.49)
(0.05 – 1.17)
0.05
baseline lactulose (%) 0.60 ± 0.10
(0.40 – 0.80)
(0.11 – 2.40)
0.53 ± 0.12
(0.28 – 0.78)
(0.06 – 1.50)
0.26
baseline lactulose/mannitol ratio 0.049 ± 0.005
(0.039 – 0.059)
(0.017 – 0.096)
0.082 ± 0.012
(0.056 – 0.108)
(0.027 – 0.184
0.01
baseline sucrose/mannitol ratio 0.038 ± 0.004
(0.029 – 0.047)
(0.008 – 0.080)
0.038 ± 0.007
(0.023 – 0.053)
(0.013 – 0.098)
0.92
baseline lactulose/xylose ratio 0.032 ± 0.003
(0.026 – 0.039)
(0.014 – 0.063)
0.050 ± 0.009
(0.030 – 0.069)
(0.017 – 0.139)
0.10
baseline sucrose/xylose ratio 0.025 ± 0.003
(0.019 – 0.031)
(0.006 – 0.058)
0.023 ± 0.004
(0.014 – 0.033)
(0.004 – 0.061)
0.64
xylose after the first dose (%) 12.9 ± 1.6
(9.5 – 16.2)
(3.7 – 34.5)
14.5 ± 3.0
(8.1 – 21.0)
(2.2 – 40.7)
0.82
mannitol after the first dose (%) 10.1 ± 1.2
(7.6 – 12.6)
(1.4 – 24.6)
8.6 ± 1.5
(5.4 – 11.7)
(2.1 – 19.2)
0.45
sucrose after the first dose (%) 0.46 ± 0.08
(0.28 – 0.63)
(0.06 – 1.71)
0.70 ± 0.14
(0.41 – 1.00)
(0.10 – 1.60)
0.12
lactulose after the first dose (%) 0.50 ± 0.08
(0.34 – 0.67)
(0.05 – 1.67)
0.87 ± 0.12
(0.62 – 1.13)
(0.50 – 2.08)
0.004
lactulose/mannitol ratio after the first dose 0.061 ± 0.009
(0.042 – 0.081)
(0.010 – 0.144)
0.171 ± 0.057
(0.047 – 0.300)
(0.030 – 0.770)
0.008
sucrose/mannitol ratio after the first dose 0.052 ± 0.009
(0.034 – 0.069)
(0.012 – 0.148)
0.123 ± 0.042
(0.032 – 0.214)
(0.020 – 0.585)
0.03
lactulose/xylose ratio after the first dose 0.050 ± 0.009
(0.031 – 0.068)
(0.007 – 0.180)
0.118 ± 0.039
(0.032 – 0.200)
(0.014 – 0.443)
0.04
sucrose/xylose ratio after the first dose 0.042 ± 0.008
(0.026 – 0.058)
(0.009 – 0.124)
0.085 ± 0.027
(0.027 – 0.143)
(0.010 – 0.336)
0.19
A total of 13 patients experienced a serious toxicity (grade 3 or 4 adverse events) during the first 6 weeks of therapy (grade 3 or 4 leukopenia 6 
patients, grade 3 diarrhea 3 patients, grade 3 nausea 3 patients, and grade 3 anemia 1 patient). Shown is the mean ± standard error of the mean 
(SEM) of respective parameters. 95% confidence intervals (CI) of the mean are highlighted by the bold type, and range is indicated in the parenthesis 
below.BMC Cancer 2007, 7:155 http://www.biomedcentral.com/1471-2407/7/155
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from the outside environment both in an immunologic
and a metabolic sense [26]. The disorders of this barrier
function may be defined by altered permeability to differ-
ent substances. 51Cr EDTA, polyvinyl pyrrolidone, or
tobramycin have been used to study intestinal permeabil-
ity in early studies [8], but recent studies have used differ-
ential urinary excretion of a disaccharide (lactulose or
cellobiose) and a monosaccharide (mannitol or rham-
nose) for the assessment of intestinal permeability. On
the other hand, increased absorption of sucrose indicates
damage to gastroduodenal mucosa. Physiologically,
sucrose is digested by sucrase in the small intestine, and
increased absorption of sucrose indicates increased per-
meability of gastric and duodenal mucosa [10]. There is
only limited information on sucrose absorption in cancer
patients. Fazeny-Dörner et al. [19] did not, in contrast to
the results of the present study, observe any changes in
sarcoma patients treated with the combination of ifosfa-
mide, doxorubicin and dacarbazine. Thus, the present
study may represent the first demonstration of increased
gastroduodenal permeability in cancer patients treated
with cytotoxic drugs.
Conclusion
A transient increase in lactulose/monosaccharide and
sucrose/monosaccharide ratios was observed in ovarian
and breast cancer patients treated with paclitaxel and plat-
inum. Increased lactulose absorption, lactulose/mannitol,
sucrose/mannitol and lactulose/xylose ratios were evident
in patients with grade 3 or 4 toxicity. Increased baseline
lactulose/mannitol predicted serious toxicity.
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